查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015025

微生物定序服務市場：依樣本類型、技術、應用和最終用戶分類－2026-2032年全球預測

Microbiome Sequencing Services Market by Sample Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，微生物組定序服務市場價值將達到 2.0684 億美元，到 2026 年將成長至 2.2076 億美元，到 2032 年將達到 2.9459 億美元，年複合成長率為 5.18%。

主要市場統計數據
基準年 2025 2.0684億美元
預計年份：2026年 2.2076億美元
預測年份 2032 2.9459億美元
複合年成長率 (%) 5.18%

重要的背景資訊揭示了技術成熟度、工作流程標準化和資料整合如何改變服務選擇和相關人員的期望。

在技​​術創新加速、應用領域日益多元化以及跨部門合作不斷加強的推動下，微生物組定序服務市場正在快速發展。本導言概述了解讀後續觀點所需的基本背景。定序方法已超越概念概念驗證階段，日趨成熟，能夠提供可重複且具有臨床應用價值的數據。檢體採集流程正朝著標準化工作流程的方向發展，從而降低樣本製備過程中的差異性。此外，運算處理流程也日趨專業化，能夠在滿足監管和隱私要求的同時處理高通量資料。總而言之，這些進步正在重新定義實驗室、診斷公司、藥物研究人員和環境專家獲取定序服務的方式，以及將定序結果整合到決策流程中的方法。

快速發展的定序方法、嚴格的工作流程標準化以及以結果為導向的夥伴關係正在重新定義服務模式和競爭差異化。

微生物組定序領域正經歷變革性的變化，涵蓋技術創新、價值鏈重組以及多體學觀點的整合。首先，定序技術正在分化。標靶擴增子定序方法針對經濟高效的分類學調查進行了最佳化，而鳥槍總體基因體學和宏轉錄組學則被引入以捕獲功能潛力和活躍基因表現。這種分化使得能夠提供差異化的服務，在速度和規模與解析度和可解釋性之間取得平衡，這要求服務供應商明確定義每種方法的效能範圍。

該評估旨在評估關稅驅動的供應鏈重組、在地採購和庫存策略如何整體定序服務的採購、檢驗和夥伴關係方式。

美國於2025年宣布的關稅措施的累積影響波及微生物組定序服務所用試劑、儀器及相關耗材的整個供應鏈。關稅帶來的成本壓力迫使供應商和終端用戶重新評估籌資策略，許多公司優先考慮供應商多元化和本地製造夥伴關係以降低風險。同時，經銷商和服務實驗室也調整了定價模式，以反映進口儀器接收成本的增加，同時也要平衡競爭壓力，避免將這些成本完全轉嫁給客戶。這種矛盾促使合約談判更加重視長期供應協議、數量保證以及供應商和客戶之間分擔庫存風險的合作安排。

詳細的細分分析揭示了檢體類型、定序技術、應用領域和最終用戶需求如何決定工作流程設計和價值提案。

細分市場分析揭示了不同檢體類型、定序技術、應用領域和最終用戶之間存在的多樣化需求趨勢和服務要求。根據檢體類型，研究和服務通常處理糞便檢體、口腔和唾液拭子、皮膚拭子、各種土壤基質以及水樣，每種樣本都存在獨特的分析前製備限制和提取挑戰，這些都會影響方案選擇和數據品質預期。例如，糞便和土壤樣本通常需要嚴格的核酸萃取和抑制劑去除步驟，而口腔和皮膚基質則更注重低生物量處理和污染控制。因此，能夠針對特定樣本類別展示檢驗的提取和品質控制工作流程的定序服務供應商，往往在臨床和環境領域更能贏得客戶的信任。

區域間投資重點、法規結構和能力分佈的差異如何影響定序服務和全球交付策略的設計和實施。

區域趨勢持續影響微生物組定序服務的投資模式、產能分佈和監管複雜性。在美洲，強勁的私營部門投資、成熟的臨床診斷生態系統以及緊密的醫藥學術網路，為結合高通量測序、高級分析和臨床級報告的複雜服務提供了支持。此外，北美客戶通常要求流程符合規範且週轉時間短，這促進了定序中心與臨床檢查室之間的夥伴關係，以確保符合嚴格的檢驗標準。

介紹各公司差異化的策略，重點在於整合、檢驗分析和協作生態系統，以加速採用並維持競爭優勢。

我們對主要企業的分析重點在於它們如何從大型服務供應商和技術供應商中脫穎而出、它們的策略定位以及它們的合作模式。市場領導往往將強大的實驗室執行能力與端到端的生物資訊結合，透過提供檢驗的流程、透明的品質保證 (QA) 指標和可重複的報告格式，滿足臨床、研究和商業客戶的需求。競爭優勢通常源自於獨特的樣本製備技術、能夠將複雜輸出轉化為決策報告的檢驗的資料解讀模組，以及支援試驗設計和監管文件的強大客戶成功能力。

為供應商提供可操作的策略和營運要求，以增強韌性、深化客戶價值並加速在所有應用程式中部署檢驗的解決方案。

隨著微生物組定序市場的日益成熟，產業領導者應採取一系列策略措施來獲取價值並降低風險。首先，應優先投資於檢驗的、針對特定應用的流程，這些流程應能在不同樣本物種中展現出可重複性，並包含清晰的品質保證/品質控制（QA/QC）關卡。這將減少客戶准入流程中的阻力，並確保在受法規環境下服務的可靠性。其次，應制定供應商多元化和區域籌資策略，以因應關稅造成的供應衝擊和物流中斷，並輔以正式的緊急時應對計畫和多供應商合格流程。第三，應投資於解釋性分析和以結果為導向的報告，將定序結果轉化為可用於臨床決策、農業管理或治療方法研發的切實可行的建議，從而提升服務的效用和感知價值。

透過文獻整合、專家訪談、技術基準測試和供應鏈診斷等系統方法，可以獲得可靠且可操作的見解。

本分析的調查方法融合了多方面的證據、相關人員訪談、技術評估和供應鏈診斷，以確保獲得可靠且可操作的見解。桌上研究整合了同儕審查文獻、技術白皮書、監管指導文件和技術藍圖，以建構對定序方法、樣本特異性限制和分析方法的理解基礎。此外，也對實驗室主任、生物資訊經理、採購專家和應用科學家進行了訪談，以補充上述二手資料研究，從而揭示已發表文獻中未必總是顯而易見的營運實際情況、應用障礙和檢驗重點。

一項綜合分析重點闡述了技術多樣性、嚴格檢驗和供應鏈韌性如何共同決定實用化和商業化的速度。

總之，微生物組定序服務的市場模式正從分散的、以調查為導向的市場轉向更結構化、應用主導的生態系統。擴增子定序、鳥槍法宏基因體學和宏轉錄組學等多種技術方法，為差異化服務模式的出現創造了機遇，以滿足不同客戶在解析度、成本和結果解讀方面的不同需求。同時，買家的期望也在發生變化，他們越來越重視工作流程標準化、檢驗的分析方法和法規遵從性，並且對結果可重複性的重要性日益凸顯。供應鏈面臨的壓力，包括關稅相關的中斷，凸顯了供應商多元化和區域生產能力的戰略價值，從而推動了近岸外包和聯合籌資策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 微生物定序服務市場樣本（按類型分類）

  • 屎
  • 口腔
  • 皮膚
  • 土壤
  • 水

第9章：微生物定序服務市場：依技術分類

  • 擴增子序列
    • 16S rRNA定序
    • 內部轉移間隔區（ITS）定序
  • 總體轉錄組定序
  • 鳥槍法元基因組組定序

第10章：微生物定序服務市場：依應用領域分類

  • 農業和畜牧業
    • 作物品質監測
    • 牲畜健康監測
  • 臨床診斷
    • 消化系統疾病的診斷
    • 感染疾病診斷
  • 消費者基因體學
    • 家庭測試
    • 醫療機構的測試
  • 環境監測
    • 土壤健康監測
    • 水質監測
  • 藥物研發
    • 藥物發現
    • 以微生物組為基礎的療法開發

第11章 微生物組定序服務市場：依最終用戶分類

  • 學術和研究機構
  • 臨床診斷檢測實驗室
  • 消費者基因組學公司
  • 合約研究機構
  • 製藥和生物製藥公司

第12章 微生物定序服務市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 微生物定序服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 微生物定序服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國微生物組定序服務市場

第16章：中國微生物定序服務市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Baseclear BV
  • BGI Group
  • Charles River Laboratories
  • Clinical Microbiomics A/S
  • CosmosID
  • Diversigen Inc.
  • Eurofins Scientific
  • Microba Life Sciences
  • Microbiome Insights Inc.
  • Molecular Research LP
  • Merieux NutriSciences Corporation
  • Novogene Co., Ltd.
  • QIAGEN NV
  • Second Genome
  • Shanghai Realbio Technology Co., Ltd.
  • Zymo Research Corporation
Product Code: MRR-036C5CF3A80E

The Microbiome Sequencing Services Market was valued at USD 206.84 million in 2025 and is projected to grow to USD 220.76 million in 2026, with a CAGR of 5.18%, reaching USD 294.59 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 206.84 million
Estimated Year [2026] USD 220.76 million
Forecast Year [2032] USD 294.59 million
CAGR (%) 5.18%

Essential contextual framing that clarifies how technological maturity, workflow standardization, and data integration are reshaping service selection and stakeholder expectations

The microbiome sequencing services landscape is evolving rapidly, driven by accelerated technological innovation, diversified applications, and intensifying cross-sector collaboration. This introduction synthesizes the essential context needed to interpret subsequent insights: sequencing modalities have matured beyond proof-of-concept to deliver reproducible, clinically relevant data; sample acquisition protocols are converging on standardized workflows that reduce pre-analytical variability; and computational pipelines are being professionalized to handle high-throughput data while meeting regulatory and privacy expectations. Taken together, these developments are redefining how laboratories, diagnostic companies, pharmaceutical researchers, and environmental practitioners procure sequencing services and integrate outputs into decision-making processes.

Importantly, this overview emphasizes the interplay between scientific capability and commercial deployment. Advances in amplicon, metatranscriptomic, and shotgun metagenomic approaches have widened the range of resolvable questions, from taxonomic profiling to functional inference and active transcriptional states. At the same time, demand patterns are shifting: clinical and pharmaceutical stakeholders require validated, compliant workflows with rapid turnaround, whereas agricultural and environmental users prioritize scalability, robustness in variable matrices such as soil and water, and cost-efficiency. Therefore, stakeholders should interpret technology choices through the lens of intended application and downstream analytics rather than as isolated technical upgrades. This framing prepares readers to assess segmentation, regional dynamics, and tactical responses to trade and policy pressures discussed in subsequent sections.

How rapidly advancing sequencing modalities, rigorous workflow standardization, and outcome-oriented partnerships are redefining service models and competitive differentiation

The microbiome sequencing sector is undergoing transformative shifts that span technological innovation, value chain reconfiguration, and integration of multi-omic perspectives. First, sequencing technology trajectories have diverged: targeted amplicon approaches are being optimized for cost-effective taxonomic surveys, while shotgun metagenomics and metatranscriptomics are being deployed to capture functional potential and active gene expression. This bifurcation enables differentiated service offerings where speed and scale are balanced against resolution and interpretability, and it compels service providers to articulate clearly the performance envelope of each modality.

Second, the rise of standardized sample handling and quality-control frameworks is diminishing variability across studies and enabling more reliable cross-cohort comparisons. This standardization, paired with improvements in bioinformatics reproducibility and containerized workflows, lowers barriers to outsourcing for clinical and industrial clients. As a result, contract research organizations and specialized sequencing centers are expanding value-added services such as validated pipelines, interpretive reporting, and regulatory support. Third, the convergence of microbiome data with clinical, agronomic, and environmental metadata is catalyzing the development of integrated analytics platforms that provide actionable insights rather than raw data alone. Consequently, successful providers are shifting from pure service delivery to outcome-oriented partnerships that emphasize problem definition, tailored experimental design, and decision-focused reporting. Finally, geopolitical and supply-chain dynamics are prompting investments in regional capacity and reagent redundancy, which in turn influence strategic partnerships and sourcing decisions across the ecosystem.

Assessing how tariff-driven supply chain realignment, localized sourcing, and inventory strategies are altering procurement, validation, and partnership approaches across sequencing services

The cumulative impact of United States tariff actions announced in 2025 has reverberated across supply chains for reagents, instrumentation, and ancillary consumables used in microbiome sequencing services. Tariff-induced cost pressures have prompted providers and end users to reexamine procurement strategies, with many prioritizing supplier diversification and local manufacturing partnerships to mitigate exposure. In parallel, distributors and service labs have recalibrated pricing models to reflect increased landed costs for imported equipment while balancing competitive pressures that limit full pass-through to customers. This tension has fuelled contract negotiations that favor longer-term supply agreements, volume commitments, and collaborative arrangements that share inventory risk between vendors and clients.

Operational responses have included stockpiling critical reagents, qualifying alternative suppliers, and accelerating validation of domestically produced consumables to ensure continuity of service. For platform manufacturers, tariff-driven margin compression has incentivized exploration of regional assembly and localized component sourcing to maintain competitiveness in key markets. At the same time, research and clinical customers have adjusted project timelines and procurement cycles to accommodate lead-time variability, and some have shifted toward higher-throughput batching strategies to optimize reagent utilization. Regulatory and compliance implications have surfaced as well; laboratories engaged in diagnostic-grade sequencing have had to ensure that validated workflows remain intact when substituting reagents or components due to tariff-related shortages. Overall, the tariff environment has heightened the strategic importance of supply chain resilience and collaborative procurement models, accelerating investments in redundancy and nearshoring that will influence suppliers' go-to-market choices and partnership architectures.

In-depth segmentation analysis revealing how sample type, sequencing technology, application domain, and end-user requirements dictate workflow design and value proposition

Segmentation insights reveal differentiated demand dynamics and service requirements across sample types, sequencing technologies, applications, and end users. Based on sample type, studies and services routinely address fecal specimens, oral swabs and saliva, skin swabs, diverse soil matrices, and water samples, each presenting unique pre-analytical constraints and extraction challenges that influence protocol selection and data quality expectations. For example, fecal and soil samples typically require robust nucleic acid extraction and inhibitor removal steps, while oral and skin matrices emphasize low-biomass handling and contamination control. Consequently, sequencing providers that can demonstrate validated extraction and QC workflows for specific sample classes often capture higher confidence from clients in clinical and environmental domains.

Based on technology, service portfolios are organized around amplicon sequencing, metatranscriptomic sequencing, and shotgun metagenomic sequencing. Amplicon sequencing is commonly subdivided into 16S rRNA sequencing for bacterial community profiling and Internal Transcribed Spacer (ITS) sequencing for fungal community characterization, offering cost-effective taxonomic resolution for many surveillance and exploratory studies. Shotgun metagenomics delivers broader taxonomic and functional resolution and is preferred when species-level discrimination and genomic context are required, while metatranscriptomic approaches reveal active gene expression patterns that inform mechanistic hypotheses and therapeutic target identification. The selection among these technologies depends on trade-offs between cost, depth, and interpretive complexity, and providers are increasingly packaging hybrid workflows to meet hybrid client needs.

Based on application, the spectrum includes Agricultural & Animal Husbandry, Clinical Diagnostics, Consumer Genomics, Environmental Monitoring, and Pharmaceutical R&D. Agricultural and animal husbandry use cases break down into crop quality monitoring and livestock health monitoring, where actionable outputs feed agronomic decisions and herd health interventions. Clinical diagnostics comprises gastrointestinal disorder diagnosis and infectious disease diagnostics, demanding validated, reproducible pipelines and regulatory alignment. Consumer genomics splits into at-home testing and clinic-based testing, where user experience, data privacy, and interpretive clarity are central. Environmental monitoring is oriented toward soil health monitoring and water quality monitoring, requiring rugged protocols that contend with diverse matrices. Pharmaceutical R&D spans drug discovery and microbiome therapeutics development, necessitating high-resolution functional insights, longitudinal sampling, and integrated omics.

Based on end user, services are tailored for academic and research institutes, clinical diagnostic laboratories, consumer genomics companies, contract research organizations, and pharmaceutical and biopharmaceutical companies. Each end-user class imposes distinct requirements for turnaround time, validation, data governance, and reporting granularity. Academic clients often prioritize methodological flexibility and raw data access, clinical labs require compliance and interpretive certainty, consumer genomics firms emphasize scale and user-friendly reports, CROs focus on programmatic integration and documentation for regulatory filings, and pharmaceutical companies demand rigorous cross-cohort comparability and integration with clinical endpoints. Recognizing these differentiated needs enables service providers to design modular offerings that map technological choices and QA practices to client-specific success criteria.

How distinct regional investment priorities, regulatory frameworks, and capacity distributions influence sequencing service design and global delivery strategies

Regional dynamics continue to shape investment patterns, capability distribution, and regulatory complexity in microbiome sequencing services. In the Americas, strong private-sector investment, a mature clinical diagnostics ecosystem, and dense pharmaceutical and academic networks support sophisticated service offerings that combine high-throughput sequencing with advanced analytics and clinical-grade reporting. In addition, North American clients frequently drive demand for regulatory-compliant pipelines and rapid turnaround, which fosters partnerships between sequencing centers and clinical laboratories to meet stringent validation standards.

Across Europe, Middle East & Africa, the landscape is heterogeneous: Western European markets emphasize rigorous data protection, well-defined clinical pathways, and collaborative public-private research consortia, while emerging markets within the region demonstrate varied capacity and growing interest in affordable, scalable surveillance solutions for environmental and agricultural applications. Regulatory harmonization efforts and cross-border research initiatives are important trends that influence both sample movement and service deployment strategies across this region.

In the Asia-Pacific region, rapid capacity expansion, significant public research investment, and a growing base of biotech companies are accelerating adoption. Providers in this region are building integrated service models that prioritize cost efficiency and scalability while addressing local language, regulatory, and logistics requirements. Collectively, these regional patterns suggest that providers seeking global reach should balance centralized high-value capabilities with strategically located regional nodes to optimize cost, compliance, and responsiveness to local end-user needs.

Profiles of differentiated company strategies emphasizing integration, validated analytics, and collaborative ecosystems that accelerate adoption and sustain competitive advantage

Key company insights focus on capabilities, strategic positioning, and collaborative models that differentiate leading service providers and technology vendors. Market leaders tend to combine robust laboratory execution with end-to-end bioinformatics, offering validated pipelines, transparent QA metrics, and reproducible reporting formats that satisfy clinical, research, and commercial clients alike. Competitive advantage is often derived from proprietary sample preparation chemistries, validated data interpretation modules that translate complex outputs into decision-ready reports, and strong customer success functions that support study design and regulatory documentation.

Many successful organizations have pursued vertical integration to control critical parts of the value chain, including reagent development, library preparation kits, and data-hosting platforms, thereby reducing reliance on third-party suppliers and improving margin visibility. Others have adopted a modular partnership strategy, creating ecosystems that link specialized sample-prep labs, sequencing centers, and interpretive analytics firms to offer flexible, scalable solutions. Strategic collaborations with pharmaceutical companies and agricultural firms are common, driven by the need to co-develop validated assays, run large-scale longitudinal studies, and translate multi-omic findings into product development hypotheses. Finally, an emerging cohort of companies is differentiating through standards leadership-investing in interlaboratory reproducibility studies, open benchmarking datasets, and participation in regulatory working groups-to build trust and lower barriers to adoption among risk-averse end users.

Actionable strategic and operational imperatives for providers to strengthen resilience, deepen client value, and accelerate validated adoption across applications

Industry leaders should adopt a portfolio of strategic actions to capture value and mitigate risk as the microbiome sequencing landscape matures. First, prioritize investment in validated, application-specific workflows that are demonstrably reproducible across sample types and that incorporate clear QA/QC gates; this reduces client onboarding friction and protects service credibility in regulated contexts. Second, develop supplier diversification and regional sourcing strategies to buffer against tariff-driven supply shocks and logistical disruptions, complemented by formal contingency plans and multi-supplier qualification processes. Third, invest in interpretive analytics and outcome-focused reporting that translate sequencing outputs into actionable recommendations for clinical decisions, agronomic management, or therapeutic development, thereby increasing the utility and perceived value of services.

Additionally, cultivate deep partnerships with end users to co-develop assays and longitudinal study frameworks that align platform capabilities with specific program objectives. This collaborative model shortens validation cycles and generates reference datasets that solidify commercial differentiation. From an operational perspective, implement modular pricing and service tiers that align with client sophistication-from raw data delivery for academic clients to turnkey, validated reports for clinical customers-so providers can capture cross-segment demand without compromising specialization. Finally, engage proactively with regulators, standards bodies, and interlaboratory consortia to influence emerging guidelines, demonstrate compliance, and build trust-actions that will lower barriers for diagnostic and therapeutic applications over time.

Methodical approach combining literature synthesis, expert interviews, technical benchmarking, and supply-chain diagnostics to produce robust actionable insights

The research methodology underpinning this analysis combined multi-source evidence synthesis, stakeholder interviews, technical assessment, and supply-chain diagnostics to ensure robust, actionable findings. Desk research synthesized peer-reviewed literature, technical white papers, regulatory guidance documents, and technology roadmaps to construct a baseline understanding of sequencing modalities, sample-specific constraints, and analytical approaches. This secondary work was complemented by targeted primary interviews with laboratory directors, bioinformatics leaders, procurement specialists, and application scientists to surface operational realities, adoption barriers, and validation priorities that are not always visible in published literature.

Technical assessments included comparative review of lab workflows and bioinformatics pipelines to evaluate reproducibility, contamination control, and interpretive clarity across amplicon, shotgun metagenomic, and metatranscriptomic approaches. Supply-chain diagnostics evaluated reagent and instrument sourcing pathways, inventory strategies, and tariff exposure to identify resilience gaps and near-term operational risks. Findings were triangulated across sources and subjected to sensitivity checks to ensure internal consistency. Where appropriate, limitations and assumptions are clearly documented to help readers interpret the implications for different end-user contexts and to guide further deep-dive analysis tailored to specific operational needs.

Consolidated synthesis highlighting how technical plurality, validation rigor, and supply-chain resilience collectively determine the pace of practical adoption and commercialization

In conclusion, the microbiome sequencing services landscape is transitioning from a fragmented research-oriented market toward a more structured, application-driven ecosystem. Technological plurality-spanning amplicon, shotgun metagenomic, and metatranscriptomic approaches-creates opportunities for differentiated service models that address distinct resolution, cost, and interpretive requirements. Concurrently, the increasing emphasis on workflow standardization, validated analytics, and regulatory alignment is reshaping buyer expectations and elevating the importance of demonstrated reproducibility. Supply-chain pressures, including tariff-related disruptions, have highlighted the strategic value of supplier diversification and regional capacity, prompting both nearshoring and collaborative procurement strategies.

For stakeholders, success depends on aligning technical capabilities with specific application needs, investing in outcome-oriented analytics, and engaging in partnerships that accelerate validation and adoption. By integrating these priorities-resilient operations, targeted productization, and proactive regulatory engagement-providers and end users can convert scientific potential into practical, decision-ready insights that deliver value across clinical, agricultural, environmental, and pharmaceutical domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Microbiome Sequencing Services Market, by Sample Type

  • 8.1. Fecal
  • 8.2. Oral
  • 8.3. Skin
  • 8.4. Soil
  • 8.5. Water

9. Microbiome Sequencing Services Market, by Technology

  • 9.1. Amplicon Sequencing
    • 9.1.1. 16S Rrna Sequencing
    • 9.1.2. Internal Transcribed Spacer Sequencing
  • 9.2. Metatranscriptomic Sequencing
  • 9.3. Shotgun Metagenomic Sequencing

10. Microbiome Sequencing Services Market, by Application

  • 10.1. Agricultural & Animal Husbandry
    • 10.1.1. Crop Quality Monitoring
    • 10.1.2. Livestock Health Monitoring
  • 10.2. Clinical Diagnostics
    • 10.2.1. Gastrointestinal Disorder Diagnosis
    • 10.2.2. Infectious Disease Diagnostics
  • 10.3. Consumer Genomics
    • 10.3.1. At-Home Testing
    • 10.3.2. Clinic-Based Testing
  • 10.4. Environmental Monitoring
    • 10.4.1. Soil Health Monitoring
    • 10.4.2. Water Quality Monitoring
  • 10.5. Pharmaceutical R&D
    • 10.5.1. Drug Discovery
    • 10.5.2. Microbiome Therapeutics Development

11. Microbiome Sequencing Services Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Clinical Diagnostic Laboratories
  • 11.3. Consumer Genomics Companies
  • 11.4. Contract Research Organizations
  • 11.5. Pharmaceutical & Biopharmaceutical Companies

12. Microbiome Sequencing Services Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Microbiome Sequencing Services Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Microbiome Sequencing Services Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Microbiome Sequencing Services Market

16. China Microbiome Sequencing Services Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Baseclear B.V.
  • 17.6. BGI Group
  • 17.7. Charles River Laboratories
  • 17.8. Clinical Microbiomics A/S
  • 17.9. CosmosID
  • 17.10. Diversigen Inc.
  • 17.11. Eurofins Scientific
  • 17.12. Microba Life Sciences
  • 17.13. Microbiome Insights Inc.
  • 17.14. Molecular Research LP
  • 17.15. Merieux NutriSciences Corporation
  • 17.16. Novogene Co., Ltd.
  • 17.17. QIAGEN N.V.
  • 17.18. Second Genome
  • 17.19. Shanghai Realbio Technology Co., Ltd.
  • 17.20. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY FECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY FECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY FECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SKIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SKIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INTERNAL TRANSCRIBED SPACER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INTERNAL TRANSCRIBED SPACER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INTERNAL TRANSCRIBED SPACER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY METATRANSCRIPTOMIC SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY METATRANSCRIPTOMIC SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY METATRANSCRIPTOMIC SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CROP QUALITY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CROP QUALITY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CROP QUALITY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY LIVESTOCK HEALTH MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY LIVESTOCK HEALTH MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY LIVESTOCK HEALTH MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY GASTROINTESTINAL DISORDER DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY GASTROINTESTINAL DISORDER DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY GASTROINTESTINAL DISORDER DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AT-HOME TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AT-HOME TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AT-HOME TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINIC-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINIC-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINIC-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL HEALTH MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL HEALTH MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SOIL HEALTH MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER QUALITY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER QUALITY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY WATER QUALITY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY MICROBIOME THERAPEUTICS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY MICROBIOME THERAPEUTICS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY MICROBIOME THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 245. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 256. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 257. NATO MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY AGRICULTURAL & ANIMAL HUSBANDRY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY CONSUMER GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY PHARMACEUTICAL R&D, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA MICROBIOME SEQUENCING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)